After a second Elevidys patient death from acute liver failure, Sarepta in July launched a major restructuring that involves a 36% mass layoff round and a pivot from gene therapy to small interfering ...

Certain Sarepta Therapeutics Inc. insiders were accused in a stockholder lawsuit of reaping a combined $6.2 million selling ...

Sarepta Therapeutics Inc.’s shares soared after the US biotech reported revenue that beat estimates, which analysts attributed in part to a milestone payment for its controversial gene therapy ...

Sarepta did not hold an investor call for its second-quarter earnings report or provide an updated full-year revenue outlook.

Jefferies analysts said these detailed safety outcomes confirm the gene therapy's positive risk/benefit profile in ambulatory ...

Sarepta Therapeutics has provided additional safety data on its gene therapy Elevidys as a Duchenne muscular dystrophy ...

The FDA’s shift on Elevidys sends a message: boldness, scientific rigor and urgency are essential in confronting rare ...

A refinancing deal will delay the maturity of $700 million in debt until 2030, allowing the company to “fully fund” its ...

Sarepta is facing a number of issues currently, including platform-level safety concerns, management credibility issues, etc.

Citi said on Wednesday that the U.S. Food and Drug Administration may take a “more comprehensive look” at the level of ...

Sarepta Therapeutics Inc. landed a deal with investors to restructure around $700 million of debt, giving the company a ...

Sarepta Therapeutics Inc. shares rose sharply early Tuesday after US regulators reversed course and recommended that patients who can walk be allowed to take its gene therapy Elevidys again.